PeptideJournal
Guides18 min read

Best Peptides for Anti-Aging & Longevity

Aging is not one thing. It is a dozen different biological processes happening simultaneously -- telomeres shortening, mitochondria losing efficiency, senescent cells accumulating, collagen degrading, hormones declining, and inflammation slowly building in tissues that used to repair themselves

Aging is not one thing. It is a dozen different biological processes happening simultaneously -- telomeres shortening, mitochondria losing efficiency, senescent cells accumulating, collagen degrading, hormones declining, and inflammation slowly building in tissues that used to repair themselves without complaint.

Peptides have become one of the most talked-about tools in longevity science because different peptides target different parts of this puzzle. Some work on the skin surface. Others act deep inside cells, at the level of mitochondria or DNA. A few are already FDA-approved for specific conditions. Many more are still moving through preclinical and early clinical research.

This guide covers the most studied anti-aging and longevity peptides, organized by what they actually do. Some have strong clinical data. Others have compelling animal research but limited human evidence. The distinction matters, and we will be clear about where each peptide stands.

Table of Contents

Understanding the Biology of Aging

Before picking peptides, it helps to understand what you are actually trying to target. Researchers have identified several "hallmarks of aging" -- biological processes that drive age-related decline. The most relevant to peptide interventions include:

Mitochondrial dysfunction. Your mitochondria produce the energy every cell needs. With age, they become less efficient, generate more damaging reactive oxygen species (ROS), and their membranes lose structural integrity. This affects everything from muscle strength to brain function.

Telomere shortening. Each time a cell divides, the protective caps on your chromosomes (telomeres) get a little shorter. When they get too short, the cell either dies or becomes senescent. Telomere length is one of the most studied biomarkers of biological age.

Cellular senescence. Senescent cells are damaged cells that stop dividing but refuse to die. They linger in tissues and pump out inflammatory signals -- a cocktail of cytokines collectively called the senescence-associated secretory phenotype (SASP). This low-grade chronic inflammation, sometimes called "inflammaging," accelerates aging in surrounding healthy cells [1].

Growth hormone and IGF-1 decline. Growth hormone production drops roughly 14% per decade after age 30. Since GH drives tissue repair, muscle maintenance, collagen synthesis, and fat metabolism, this decline shows up as thinner skin, reduced muscle mass, increased abdominal fat, and slower recovery.

Extracellular matrix degradation. Collagen, elastin, and other structural proteins that hold tissues together break down faster than they are replaced. In skin, this means wrinkles and sagging. In joints, cartilage loss. In blood vessels, reduced elasticity.

Metabolic dysfunction. Insulin resistance, impaired fat oxidation, and declining NAD+ levels all contribute to age-related metabolic changes that increase disease risk.

Different peptides address different hallmarks. The most effective longevity strategies combine interventions that work across multiple pathways.

Skin Anti-Aging Peptides

The most visible effects of aging happen at the skin level. These peptides have the strongest evidence for topical and cosmetic anti-aging.

GHK-Cu: The Copper Peptide

GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) found in human blood plasma. It was first isolated in 1973 as a factor that caused old human liver tissue to synthesize proteins like younger tissue. GHK has a high affinity for copper, forming the chelate GHK-Cu [2].

Here is what makes GHK-Cu remarkable: your blood levels of it drop sharply with age. At 20, you have about 200 ng/ml. By 60, that number falls to around 80 ng/ml [2]. This decline correlates with many of the changes we associate with aging skin.

What the research shows:

GHK-Cu stimulates collagen I, III, and IV production, increases elastin synthesis, and promotes glycosaminoglycan formation in dermal fibroblasts. In one study, all tested concentrations (0.01 to 100 nM) increased both collagen and elastin production [3].

A randomized, double-blind clinical trial found that GHK-Cu encapsulated in nano-lipid carriers reduced wrinkle volume by 55.8% and wrinkle depth by 32.8% compared to control serum after 8 weeks. Compared to Matrixyl 3000, GHK-Cu reduced wrinkle volume by 31.6% [3].

Beyond skin, GHK-Cu influences an enormous number of genes. Using the Broad Institute's Connectivity Map, researchers found it modulates expression of 4,000+ human genes -- roughly 6% of the human genome. It upregulates 47 DNA repair genes and suppresses NF-kB, a master switch for inflammatory gene expression [4].

An intranasal GHK-Cu study in 20-month-old mice (equivalent to roughly 65 in human years) showed that two months of daily treatment improved spatial memory and learning while decreasing neuroinflammation and axonal damage markers [5].

Evidence level: Strong in vitro and animal data. Solid clinical evidence for topical skin benefits. Preliminary but promising cognitive research.

Matrixyl (Palmitoyl Pentapeptide-4)

Matrixyl is the most clinically studied signal peptide in skincare. It mimics a fragment of collagen I and tells fibroblasts to produce more collagen types I, III, and IV, along with hyaluronic acid.

A 12-week double-blind, placebo-controlled study on 93 women showed significant improvement in fine lines compared to placebo [6]. In a shorter 28-day study, 0.005% applied twice daily around the eye reduced wrinkle fold depth by 18% and fold thickness by 37% [7].

Lab data is even more impressive. Studies report up to 117% increase in overall collagen synthesis and up to 327% increase in collagen IV [7]. Matrixyl 3000 -- the next-generation version combining palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 -- reduced deep wrinkle area by 45% after 2 months in clinical testing [8].

For more detail, see our Best Peptides for Skin Anti-Aging guide.

Evidence level: Strong clinical evidence for topical wrinkle reduction. Well-established safety profile.

Argireline (Acetyl Hexapeptide-8)

Argireline takes a completely different approach to skin aging. Instead of building collagen, it reduces the muscle contractions that create expression lines -- crow's feet, forehead furrows, the "11" lines between your brows.

It works by acting as a competitive inhibitor of SNAP-25, a protein required for neurotransmitter release at the neuromuscular junction. The effect is similar to botulinum toxin but far milder and entirely topical [9].

A randomized, placebo-controlled study in 60 Chinese subjects found that 4 weeks of twice-daily application reduced periorbital wrinkle roughness significantly (p < 0.01), while the placebo group showed no measurable change. The total anti-wrinkle efficacy rate was 48.9% in the treatment group versus 0% in the placebo group [10].

At 10% concentration, Argireline reduced wrinkle depth by up to 30% after 30 days [9]. It is less potent than Botox injections, but the tradeoff is zero risk of the side effects associated with injectable neurotoxins.

Evidence level: Solid clinical evidence for superficial wrinkle reduction. Safe over-the-counter option. Limited skin penetration remains a challenge.

Mitochondrial Peptides

This is where anti-aging peptide research gets genuinely exciting. Mitochondrial-derived peptides (MDPs) are encoded not by nuclear DNA, but by mitochondrial DNA. They act as retrograde signals -- messages from mitochondria to the rest of the cell and body.

MOTS-c: The Exercise Mimetic

MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C) is a 16-amino-acid peptide that activates AMPK, the same metabolic master switch triggered by exercise and caloric restriction. It increases glucose uptake, improves fatty acid oxidation, and stimulates mitochondrial biogenesis [11].

What the research shows:

MOTS-c levels decline with age in both human serum and mouse tissues. In old mice, MOTS-c injection reversed age-related skeletal muscle insulin resistance and improved glucose tolerance [12].

Treated mice showed a 6.4% increase in median lifespan and 7% increase in maximum lifespan. Even in old age, MOTS-c improved treadmill performance and physical endurance [12].

A 2025 study published in Nature's Experimental & Molecular Medicine found that MOTS-c treatment reduced pancreatic cell senescence and improved glucose metabolism in aged mice. In humans, circulating MOTS-c levels are lower in type 2 diabetes patients compared to healthy controls [13].

The peptide also improved heart function in diabetic models by restoring mitochondrial respiration -- a finding published in Frontiers in Physiology in 2025 [14].

Evidence level: Strong preclinical evidence. No human clinical trials yet. Synthetic analogs (like CB411) are being developed for better stability.

Humanin: The Neuroprotective Peptide

Humanin is a 24-amino-acid peptide discovered in 2001 from an unusual source: postmortem brain tissue from an Alzheimer's disease patient, specifically from the occipital lobe -- a region that stays relatively intact during AD [15].

What the research shows:

Humanin levels decline with age across multiple species. But in naked mole-rats -- the longest-lived rodents, which show negligible senescence -- humanin levels remain stable over two decades. Even more striking, children of centenarians have significantly higher circulating humanin than age-matched controls [16].

In C. elegans (roundworms), overexpression of humanin is sufficient to extend lifespan in a FOXO-dependent manner. In mice, twice-weekly treatment with the humanin analog HNG improved metabolic health and reduced inflammatory markers in middle-aged animals [16].

Humanin protects neurons against amyloid-beta toxicity both in vitro and in vivo. Mice given humanin are protected from memory deficits caused by Alzheimer's-associated proteins. A study in Scientific Reports found that humanin administration prevented age-related cognitive decline in mice and, in a large human cohort, a specific mitochondrial SNP in the humanin-coding region was associated with accelerated cognitive aging [17].

Evidence level: Strong preclinical data across multiple species. Compelling human correlational data (centenarian studies, genetic associations). No direct human clinical trials yet.

SS-31 (Elamipretide): Mitochondrial Membrane Repair

SS-31 (Elamipretide) is a synthetic tetrapeptide that targets cardiolipin, a phospholipid in the inner mitochondrial membrane that is critical for electron transport chain function. Unlike most peptides that work through receptors, SS-31 works by physically interacting with mitochondrial membrane components [18].

What the research shows:

In aged mice, 8 weeks of SS-31 treatment reversed age-related diastolic heart dysfunction -- a common and previously considered irreversible feature of cardiac aging [19]. In skeletal muscle, prolonged SS-31 treatment restored redox homeostasis, improved mitochondrial quality, and increased exercise tolerance [18].

SS-31 has the most advanced clinical pipeline of any mitochondrial peptide. In September 2025, the FDA granted accelerated approval for elamipretide to treat Barth syndrome, a rare mitochondrial disorder causing weakened hearts and shortened lifespans. Patients in the extension trial improved six-minute walking distance by an average of 96.1 meters and showed improved cardiac stroke volume [20].

It has also been granted Fast Track designation for primary mitochondrial myopathy and Leber's Hereditary Optic Neuropathy. Phase I heart failure trials showed significant reductions in left ventricular volumes with high-dose infusion [20].

Evidence level: Strong preclinical and clinical data. FDA-approved for Barth syndrome. Multiple ongoing clinical trials in aging-related conditions.

Telomere and Cellular Aging Peptides

These peptides target two of the most fundamental mechanisms of aging: telomere shortening and senescent cell accumulation.

Epitalon: Telomerase Activation

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) identified as the active component of epithalamin, a bovine pineal gland extract studied for decades at the St. Petersburg Institute of Bioregulation and Gerontology.

What the research shows:

The foundational 2003 study by Khavinson showed that Epitalon reactivated telomerase in human fetal fibroblasts, extending telomere length enough to surpass the Hayflick limit -- the maximum number of times a normal cell can divide [21].

A recent study published in Biogerontology expanded these findings, showing dose-dependent telomere extension in multiple cell types. The research also revealed that Epitalon works through two mechanisms: telomerase activation and alternative lengthening of telomeres (ALT) [22].

Beyond telomeres, Epitalon increased antioxidant enzyme activities (SOD, glutathione peroxidase, glutathione-S-transferase) in aging rats, reduced chromosomal aberrations in aging mice, and decreased spontaneous tumor formation [23].

A human prospective cohort study of 266 people over age 60 found that epithalamin treatment produced a 1.6-1.8x reduction in mortality over the following 6 years. When combined with thymalin, mortality was reduced 2.5-fold. Annual combined treatment yielded a 4.1-fold mortality reduction [23].

Epitalon also appears to restore melatonin secretion from the pineal gland in aged monkeys and humans -- a relevant finding since melatonin decline is a well-established feature of aging [23].

Evidence level: Consistent in vitro and animal evidence. One notable human cohort study. Most research originates from a single research group in Russia, which limits independent validation. Growing international interest with recent studies from other institutions.

FOXO4-DRI: Senolytic Peptide

FOXO4-DRI is a synthetic peptide designed to selectively kill senescent cells. It works by disrupting the interaction between FOXO4 and p53 -- a molecular handshake that keeps damaged, senescent cells alive. When FOXO4-DRI breaks this interaction, p53 redirects to mitochondria and triggers apoptosis specifically in senescent cells [24].

What the research shows:

In vitro, FOXO4-DRI showed an 11.73-fold selectivity for senescent cells versus normal cells -- meaning it potently killed senescent cells while leaving healthy cells essentially unaffected [24].

In aged mice, FOXO4-DRI improved the testicular microenvironment and partially restored age-related testosterone decline by clearing senescent Leydig cells [25]. In chondrocyte cultures, it selectively removed senescent cells that accumulate during in vitro expansion for cartilage repair procedures [26].

A 2025 study in Nature Communications provided detailed structural insights into the FOXO4-p53 interaction, informing the design of next-generation senolytic peptides [27]. Research published in Frontiers in Bioengineering and Biotechnology (2025) demonstrated that FOXO4-DRI improved vascular function and delayed vascular aging through the p53/BCL-2/Caspase-3 pathway [28].

Evidence level: Promising preclinical data. Highly specific mechanism. No human clinical trials yet, but D-retro-inverso peptides have shown safety in clinical trials for other indications.

Growth Hormone Peptides

Growth hormone (GH) is one of the most tangible hormonal declines of aging. These peptides stimulate your body's own GH production rather than replacing it directly.

Sermorelin

Sermorelin is a synthetic version of the first 29 amino acids of GHRH. Because it works through the pituitary gland's natural feedback loops, GH release is pulsatile rather than the constant elevation seen with direct GH injections. This preserves the hypothalamic-pituitary axis and avoids the tolerance that develops with exogenous GH [29].

Clinical observations report improvements in skin texture, body composition, and sleep quality over 6-12 months [29].

Tesamorelin

Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has the strongest clinical evidence of any GH peptide for body composition improvement.

CJC-1295 and Ipamorelin

CJC-1295 and Ipamorelin are often combined in anti-aging clinics to produce stronger, more sustained GH pulses. Human data from controlled trials is limited. The FDA has flagged safety concerns with compounded versions [30].

For deeper coverage, see our profiles on MK-677 and CJC-1295 with DAC.

Metabolic and Immune Peptides

Metabolic health and immune function are two of the biggest drivers of how well -- or how poorly -- you age.

Semaglutide and GLP-1 Agonists

Semaglutide and Tirzepatide have the strongest clinical evidence of any peptides for metabolic health, which makes them arguably the most impactful anti-aging peptides available today. That claim might sound surprising for "weight loss drugs," but the logic is straightforward: metabolic dysfunction is one of the primary drivers of age-related disease.

These peptides produce 15-20% body weight loss in clinical trials, improve insulin sensitivity, reduce cardiovascular events, and lower inflammatory markers. The SELECT trial showed semaglutide reduced major cardiovascular events by 20% in people with obesity -- outcomes that directly extend healthspan [31].

Evidence level: Phase III clinical trial data. FDA-approved. The strongest evidence base of any peptide on this list for reducing age-related disease risk.

Thymosin Alpha-1

Thymosin Alpha-1 is a 28-amino-acid peptide that restores immune function by promoting T cell maturation and differentiation. It is approved in over 35 countries for hepatitis B, hepatitis C, and cancer immunotherapy support.

As you age, your thymus shrinks and T cell production declines -- a process called immunosenescence. Ta1 counteracts this by acting through Toll-like receptors on dendritic cells, upregulating CD4+ T cells and improving the CD4+/CD8+ ratio [32].

For detailed coverage, see our Best Peptides for Immune Support guide.

BPC-157

BPC-157 is a 15-amino-acid peptide derived from human gastric juice with broad tissue-healing properties in animal models -- accelerating collagen deposition, angiogenesis, and inflammation resolution [33]. Human clinical data remains extremely limited.

Anti-Aging Peptides Comparison Table

PeptidePrimary TargetEvidence LevelDeliveryFDA Status
GHK-CuSkin, collagen, gene expressionClinical trials (topical)Topical, injectableOTC (topical)
MatrixylCollagen synthesisClinical trialsTopicalOTC cosmetic
ArgirelineExpression wrinklesClinical trialsTopicalOTC cosmetic
MOTS-cMitochondria, metabolismAnimal studiesInjectableNot approved
HumaninNeuroprotection, metabolismAnimal + correlational humanInjectableNot approved
SS-31Mitochondrial membranesClinical trialsInjectableFDA-approved (Barth)
EpitalonTelomerase, telomeresCell + animal + limited humanInjectableNot approved
FOXO4-DRISenescent cell clearanceAnimal studiesInjectableNot approved
SermorelinGrowth hormone axisClinical dataInjectablePreviously approved
TesamorelinGrowth hormone, visceral fatClinical trialsInjectableFDA-approved
SemaglutideMetabolism, cardiovascularLarge Phase III trialsInjectable, oralFDA-approved
Thymosin Alpha-1Immune functionClinical trialsInjectableApproved (35+ countries)

What About Stacking Peptides for Longevity?

The concept behind peptide stacking for longevity is straightforward: since aging involves multiple simultaneous processes, combining peptides that target different hallmarks could produce synergistic benefits.

A theoretical longevity stack might address:

  • Mitochondrial function (MOTS-c or SS-31) + Telomere maintenance (Epitalon) + Immune restoration (Thymosin Alpha-1) + Skin and tissue repair (GHK-Cu topically)

However, this approach has a significant limitation: no controlled studies have tested multi-peptide longevity protocols in humans. The interactions between peptides -- whether synergistic, neutral, or counterproductive -- remain largely unstudied.

For practical stacking information, see our Peptide Stacking Guide.

The Lifestyle Foundation Still Matters

No peptide -- no matter how promising -- replaces the fundamentals of healthy aging. The interventions with the strongest evidence for extending healthspan remain:

  • Exercise (both resistance training and cardiovascular), which naturally activates many of the same pathways these peptides target, including AMPK, mTOR regulation, and mitochondrial biogenesis
  • Nutrition with adequate protein, micronutrient diversity, and limited ultra-processed food
  • Sleep quality of 7-9 hours, which directly affects growth hormone secretion, immune function, and cellular repair
  • Stress management, since chronic psychological stress accelerates telomere shortening and increases inflammatory markers
  • Blood glucose and blood pressure control, the two metabolic parameters most consistently linked to healthy aging outcomes

Peptides are tools that may augment a solid foundation. They are not substitutes for it.

Frequently Asked Questions

What is the most proven anti-aging peptide? For skin aging, GHK-Cu and Matrixyl have the strongest clinical evidence. For overall healthspan and disease prevention, GLP-1 agonists like semaglutide have the largest and most rigorous clinical trial data. For mitochondrial aging, SS-31 (elamipretide) has reached FDA approval for Barth syndrome and is in trials for other conditions.

Are anti-aging peptides safe? Safety varies enormously between peptides. Topical peptides like Matrixyl and Argireline have excellent safety profiles. FDA-approved peptides like semaglutide and tesamorelin have well-characterized side effect profiles from large clinical trials. Research peptides like FOXO4-DRI and MOTS-c have limited human safety data. The source and purity of peptide products also matters -- compounded and "research-grade" peptides lack the quality control of pharmaceutical products.

Can peptides actually reverse aging? Some peptides can reverse specific aspects of aging in laboratory and animal models. SS-31 reversed age-related cardiac dysfunction in mice. GHK-Cu made old liver cells behave like younger ones. FOXO4-DRI cleared senescent cells in aged mice. But "reversing aging" as a whole is a claim no peptide can currently support. Aging is too complex and multi-factorial for any single intervention to reverse it completely.

Do I need a prescription for anti-aging peptides? Topical peptides (GHK-Cu serums, Matrixyl products, Argireline) are available over the counter. FDA-approved peptides like semaglutide and tesamorelin require prescriptions. Many other peptides discussed here are available as "research chemicals" but are not approved for human use, which raises quality, legality, and safety concerns.

What is the best age to start using anti-aging peptides? For topical skin peptides, your late 20s to early 30s is a reasonable starting point -- collagen production begins declining around age 25. For systemic peptides targeting deeper aging mechanisms, there is no established "best age," and decisions should be made with a physician based on individual health status and risk factors.

How long do peptides take to work for anti-aging? Topical peptides typically show measurable skin improvements in 4-12 weeks. Growth hormone peptides require 3-6 months for noticeable body composition and skin changes. Mitochondrial and telomere-targeting peptides may require months to years of use, and their effects are better measured through biomarkers than visible changes.

The Bottom Line

The anti-aging peptide field is split between two realities. On one side, you have peptides with strong evidence: GLP-1 agonists that reduce cardiovascular disease and metabolic dysfunction; topical peptides like GHK-Cu and Matrixyl that measurably improve skin aging; and SS-31, which has earned FDA approval by fixing mitochondrial function in specific diseases.

On the other side, you have peptides with fascinating science but incomplete evidence: MOTS-c as an exercise mimetic, Epitalon for telomerase activation, FOXO4-DRI for clearing senescent cells, and Humanin for neuroprotection. These peptides target real mechanisms of aging, and their preclinical data is genuinely compelling. But they have not yet been tested rigorously in human longevity studies.

The smart approach is to match your expectations to the evidence. Use well-studied topical peptides for skin. Work with a physician on any systemic peptide protocols. Pay attention to the research as it develops -- what we know in 2026 is substantially more than we knew even two years ago. And above all, do not let the excitement about peptides distract from the proven foundations of healthy aging that remain your highest-leverage interventions.

References

  1. Lopez-Otin C, et al. "Hallmarks of aging: An expanding universe." Cell. 2023;186(2):243-278. PubMed

  2. Pickart L, Margolina A. "The potential of GHK as an anti-aging peptide." Aging Pathobiology and Therapeutics. 2022;4(1):14-27. PMC

  3. Badenhorst T, et al. "Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters." Journal of Aging Science. 2016;4(1):166. Full text

  4. Pickart L, et al. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences. 2018;19(7):1987. PMC

  5. Mack JM, et al. "Intranasal GHK peptide enhances resilience to cognitive decline in aging mice." GeroScience. 2023;46:2455-2468. PMC

  6. Robinson LR, et al. "Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin." International Journal of Cosmetic Science. 2005;27(3):155-160. PubMed

  7. Lintner K, et al. "Topical peptide treatments with effective anti-aging results." Cosmetics. 2017;4(2):16. MDPI

  8. Sederma. "Matrixyl 3000 Clinical Studies." Technical data. Sederma

  9. "Acetyl Hexapeptide-8 in Cosmeceuticals -- A Review of Skin Permeability and Efficacy." International Journal of Molecular Sciences. 2025;26(12):5722. PMC

  10. Wang Y, et al. "The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study." American Journal of Clinical Dermatology. 2013;14(2):147-53. PubMed

  11. Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism. 2015;21(3):443-454. PubMed

  12. Reynolds JC, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications. 2021;12:470. PMC

  13. "Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes." Experimental & Molecular Medicine. 2025. Nature

  14. "Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart." Frontiers in Physiology. 2025. Frontiers

  15. Hashimoto Y, et al. "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta." Proceedings of the National Academy of Sciences. 2001;98(11):6336-6341. PubMed

  16. Cobb LJ, et al. "The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan." Aging. 2020;12(12):11185-11199. PMC

  17. Yen K, et al. "Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans." Scientific Reports. 2018;8:14212. Nature

  18. Siegel MP, et al. "Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice." Free Radical Biology and Medicine. 2013;68:174-184. PMC

  19. Chiao YA, et al. "Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice." eLife. 2020;9:e55513. eLife

  20. "FDA approves drug for treatment of rare mitochondrial disorder." Johns Hopkins Hub. September 2025. JHU Hub

  21. Khavinson VK, et al. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. PubMed

  22. "Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity." Biogerontology. 2025. Springer

  23. "Epitalon." Wikipedia summary of primary research. Wikipedia

  24. Baar MP, et al. "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging." Cell. 2017;169(1):132-147. PMC

  25. Zhang L, et al. "FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice." Aging. 2020;12(4):3069-3088. PMC

  26. Schieber T, et al. "Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes." Frontiers in Bioengineering and Biotechnology. 2021;9:677576. PMC

  27. "The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI." Nature Communications. 2025. Nature

  28. "FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway." Frontiers in Bioengineering and Biotechnology. 2025. Frontiers

  29. Walker RF. "Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging. 2006;1(4):307-308. PMC

  30. FDA. "FDA warns consumers about the potential risks of compounded peptide products." 2023.

  31. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. 2023;389:2221-2232. PubMed

  32. Romani L, et al. "Thymosin alpha 1: an endogenous regulator of inflammation, immunity, and tolerance." Annals of the New York Academy of Sciences. 2012;1270:45-51. PubMed

  33. Seiwerth S, et al. "BPC 157's effect on healing." Journal of Physiology (Paris). 1997;91:173-178. PubMed